The transcription factors Runx3 and ThPOK cross-regulate acquisition of cytotoxic function by human Th1 lymphocytes

  1. Yasmina Serroukh
  2. Chunyan Gu-Trantien
  3. Baharak Hooshiar Kashani
  4. Matthieu Defrance
  5. Thien-Phong Vu Manh
  6. Abdulkader Azouz
  7. Aurélie Detavernier
  8. Alice Hoyois
  9. Jishnu Das
  10. Martin Bizet
  11. Emeline Pollet
  12. Tressy Tabbuso
  13. Emilie Calonne
  14. Klaas van Gisbergen
  15. Marc Dalod
  16. François Fuks
  17. Stanislas Goriely
  18. Arnaud Marchant  Is a corresponding author
  1. Université Libre de Bruxelles, Belgium
  2. Aix Marseille Univ, CNRS, INSERM U1104, France
  3. Ragon Institute of MGH, MIT and Harvard, United States
  4. Sanquin Research and Landsteiner Laboratory AMC/UvA, Netherlands

Abstract

Cytotoxic CD4 (CD4CTX) T cells are emerging as an important component of anti-viral and anti-tumor immunity but the molecular basis of their development remains poorly understood. In the context of human cytomegalovirus infection, a significant proportion of CD4 T cells displays cytotoxic functions. We observed that the transcriptional program of these cells was enriched in CD8 T cell lineage genes despite the absence of ThPOK downregulation. We further show that establishment of CD4CTX-specific transcriptional and epigenetic programs occurred in a stepwise fashion along the Th1-differentiation pathway. In vitro, prolonged activation of naive CD4 T cells in presence of Th1 polarizing cytokines led to the acquisition of perforin-dependent cytotoxic activity. This process was dependent on the Th1 transcription factor Runx3 and was limited by the sustained expression of ThPOK. This work elucidates the molecular program of human CD4CTX T cells and identifies potential targets for immunotherapy against viral infections and cancer.

Data availability

The following data sets were generated

Article and author information

Author details

  1. Yasmina Serroukh

    Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  2. Chunyan Gu-Trantien

    Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  3. Baharak Hooshiar Kashani

    Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  4. Matthieu Defrance

    Laboratoire d'Epigénétique du Cancer, Université Libre de Bruxelles, Brussels, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  5. Thien-Phong Vu Manh

    Centre d'Immunologie de Marseille-Luminy, Aix Marseille Univ, CNRS, INSERM U1104, Marseille, France
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-0294-342X
  6. Abdulkader Azouz

    Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  7. Aurélie Detavernier

    Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  8. Alice Hoyois

    Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  9. Jishnu Das

    Ragon Institute of MGH, MIT and Harvard, Cambridge, United States
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-5747-064X
  10. Martin Bizet

    Laboratoire d'Epigénétique du Cancer, Université Libre de Bruxelles, Brussels, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  11. Emeline Pollet

    Centre d'Immunologie de Marseille-Luminy, Aix Marseille Univ, CNRS, INSERM U1104, Marseille, France
    Competing interests
    The authors declare that no competing interests exist.
  12. Tressy Tabbuso

    Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  13. Emilie Calonne

    Laboratoire d'Epigénétique du Cancer, Université Libre de Bruxelles, Brussels, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  14. Klaas van Gisbergen

    Department of Haematopoiesis, Sanquin Research and Landsteiner Laboratory AMC/UvA, Amsterdam, Netherlands
    Competing interests
    The authors declare that no competing interests exist.
  15. Marc Dalod

    Centre d'Immunologie de Marseille-Luminy, Aix Marseille Univ, CNRS, INSERM U1104, Marseille, France
    Competing interests
    The authors declare that no competing interests exist.
  16. François Fuks

    Laboratoire d'Epigénétique du Cancer, Université Libre de Bruxelles, Brussels, Belgium
    Competing interests
    The authors declare that no competing interests exist.
  17. Stanislas Goriely

    Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-7005-6195
  18. Arnaud Marchant

    Institute for Medical Immunology, Université Libre de Bruxelles, Charleroi, Belgium
    For correspondence
    arnaud.marchant@ulb.ac.be
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-0578-0467

Funding

Fonds De La Recherche Scientifique - FNRS (PhD Student Fellowship)

  • Yasmina Serroukh

Belgian Federal Public Planning Service Science Policy (Research Project Grant)

  • Stanislas Goriely
  • Arnaud Marchant

European Regional Development Fund and Walloon Region (Research Project Grant (411132-957270))

  • Stanislas Goriely
  • Arnaud Marchant

Fonds De La Recherche Scientifique - FNRS (Research Project Grant (PDR))

  • François Fuks
  • Stanislas Goriely
  • Arnaud Marchant

Fonds Erasme (PhD Student Fellowship)

  • Alice Hoyois

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Human subjects: Volunteers were recruited by the research centre ImmuneHealth, CHU Tivoli, La Louvière. Clinical staff informed the volunteers about the objectives of the study and obtained their written consent to use the human material for research purposes. The study and the informed consent form were approved , following approval by the Ethics committee of the CHU Tivoli, La Louvière, Belgium (Reference B09620097253). The study followed the Good Clinical Practice (ICH/GCP) guidelines, the Belgian Law and the declaration of Helsinki ("World Medical Association Declaration of Helsinki; Ethical Principles for Medical Research Involving Human Subjects").

Copyright

© 2018, Serroukh et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Yasmina Serroukh
  2. Chunyan Gu-Trantien
  3. Baharak Hooshiar Kashani
  4. Matthieu Defrance
  5. Thien-Phong Vu Manh
  6. Abdulkader Azouz
  7. Aurélie Detavernier
  8. Alice Hoyois
  9. Jishnu Das
  10. Martin Bizet
  11. Emeline Pollet
  12. Tressy Tabbuso
  13. Emilie Calonne
  14. Klaas van Gisbergen
  15. Marc Dalod
  16. François Fuks
  17. Stanislas Goriely
  18. Arnaud Marchant
(2018)
The transcription factors Runx3 and ThPOK cross-regulate acquisition of cytotoxic function by human Th1 lymphocytes
eLife 7:e30496.
https://doi.org/10.7554/eLife.30496

Share this article

https://doi.org/10.7554/eLife.30496

Further reading

    1. Immunology and Inflammation
    2. Microbiology and Infectious Disease
    Ainhoa Arbués, Sarah Schmidiger ... Damien Portevin
    Research Article

    The members of the Mycobacterium tuberculosis complex (MTBC) causing human tuberculosis comprise 10 phylogenetic lineages that differ in their geographical distribution. The human consequences of this phylogenetic diversity remain poorly understood. Here, we assessed the phenotypic properties at the host-pathogen interface of 14 clinical strains representing five major MTBC lineages. Using a human in vitro granuloma model combined with bacterial load assessment, microscopy, flow cytometry, and multiplexed-bead arrays, we observed considerable intra-lineage diversity. Yet, modern lineages were overall associated with increased growth rate and more pronounced granulomatous responses. MTBC lineages exhibited distinct propensities to accumulate triglyceride lipid droplets—a phenotype associated with dormancy—that was particularly pronounced in lineage 2 and reduced in lineage 3 strains. The most favorable granuloma responses were associated with strong CD4 and CD8 T cell activation as well as inflammatory responses mediated by CXCL9, granzyme B, and TNF. Both of which showed consistent negative correlation with bacterial proliferation across genetically distant MTBC strains of different lineages. Taken together, our data indicate that different virulence strategies and protective immune traits associate with MTBC genetic diversity at lineage and strain level.

    1. Immunology and Inflammation
    2. Medicine
    Haiyi Fei, Xiaowen Lu ... Lingling Jiang
    Research Article

    Preeclampsia (PE), a major cause of maternal and perinatal mortality with highly heterogeneous causes and symptoms, is usually complicated by gestational diabetes mellitus (GDM). However, a comprehensive understanding of the immune microenvironment in the placenta of PE and the differences between PE and GDM is still lacking. In this study, cytometry by time of flight indicated that the frequencies of memory-like Th17 cells (CD45RACCR7+IL-17A+CD4+), memory-like CD8+ T cells (CD38+CXCR3CCR7+HeliosCD127CD8+) and pro-inflam Macs (CD206CD163CD38midCD107alowCD86midHLA-DRmidCD14+) were increased, while the frequencies of anti-inflam Macs (CD206+CD163CD86midCD33+HLA-DR+CD14+) and granulocyte myeloid-derived suppressor cells (gMDSCs, CD11b+CD15hiHLA-DRlow) were decreased in the placenta of PE compared with that of normal pregnancy (NP), but not in that of GDM or GDM&PE. The pro-inflam Macs were positively correlated with memory-like Th17 cells and memory-like CD8+ T cells but negatively correlated with gMDSCs. Single-cell RNA sequencing revealed that transferring the F4/80+CD206 pro-inflam Macs with a Folr2+Ccl7+Ccl8+C1qa+C1qb+C1qc+ phenotype from the uterus of PE mice to normal pregnant mice induced the production of memory-like IL-17a+Rora+Il1r1+TNF+Cxcr6+S100a4+CD44+ Th17 cells via IGF1–IGF1R, which contributed to the development and recurrence of PE. Pro-inflam Macs also induced the production of memory-like CD8+ T cells but inhibited the production of Ly6g+S100a8+S100a9+Retnlg+Wfdc21+ gMDSCs at the maternal–fetal interface, leading to PE-like symptoms in mice. In conclusion, this study revealed the PE-specific immune cell network, which was regulated by pro-inflam Macs, providing new ideas about the pathogenesis of PE.